A5006193234- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Long-Term Effects of COVID-19
- COVID-19 and healthcare impacts
- COVID-19 Impact on Reproduction
- Mycobacterium research and diagnosis
- Vaccine Coverage and Hesitancy
- Cytomegalovirus and herpesvirus research
- COVID-19 epidemiological studies
- Parvovirus B19 Infection Studies
- Viral gastroenteritis research and epidemiology
- Streptococcal Infections and Treatments
- Animal Virus Infections Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Renal Transplantation Outcomes and Treatments
- Bartonella species infections research
- Herpesvirus Infections and Treatments
- Biosensors and Analytical Detection
- Pharmacological Effects and Toxicity Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Rabies epidemiology and control
- Biomedical Research and Pathophysiology
- Drug Transport and Resistance Mechanisms
- Infectious Diseases and Mycology
Cliniques Universitaires Saint-Luc
2018-2024
UCLouvain
2013-2024
Directorate-General Joint Research Centre
2021
The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to decrease the risk progression severe COVID-19 in high-risk patients has been demonstrated. However, evidence infected kidney transplant recipients (KTRs) is lacking. Moreover, NR significant and potentially harmful interactions with calcineurin inhibitors (CNIs).In this single-center retrospective study, we included all KTRs treated from April 28 June 3, 2022. A standard management strategy CNI dose adaptation...
The world is facing a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although kidney transplant recipients are at increased risk for viral infections, the impact of their chronic immunosuppressed status on acquiring disease 2019 (COVID-19) and severity unknown.All cases COVID-19 infection in our cohort were prospectively monitored. Clinical features, management, outcomes recorded. A standard strategy immunosuppression minimization was applied:...
Abstract Background The severity of coronavirus disease 2019 (COVID-19) is highly variable between individuals, ranging from asymptomatic infection to critical with acute respiratory distress syndrome requiring mechanical ventilation. Such variability stresses the need for novel biomarkers associated outcome. As SARS-CoV-2 causes a kidney proximal tubule dysfunction urinary loss uric acid, we hypothesized that low serum levels acid (hypouricemia) may be and outcome COVID-19. Methods In...
More than a year after the start of pandemic, COVID-19 remains global health emergency. Although immune response against SARS-CoV-2 has been extensively studied, some points remain controversial. One is role antibodies in viral clearance and modulation disease severity. While passive transfer neutralizing protects infection animal models, titers anti-SARS-CoV-2 have reported to be higher patients suffering from more severe forms disease. A second key question for pandemic management vaccine...
Coronavirus disease 2019 , which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly life threatening in patients who are immunocompromised, including those with advanced chronic kidney (CKD) [1,2].Despite the implementation of a third dose messenger RNA (mRNA) vaccine, efficacy SARS-CoV-2 vaccination on humoral and cellular immunities reduced population CKD, resulting an increased incidence infection mortality, fully vaccinated [3].In this context,...
Abstract The kinetics of IgG antibodies after coronavirus disease 2019 (COVID‐19) remain poorly understood. We investigated factors influencing severe acute respiratory syndrome 2 (SARS‐CoV‐2) antibody levels and time to seronegativation during the follow‐up critically ill patients. retrospectively reviewed serological evaluations drawn or critical laboratory‐proven COVID‐19 patients hospitalized at a large academic hospital. Specific titers were measured using chemiluminescent assay...
Neutralizing monoclonal antibody treatments have shown promising preliminary results in kidney transplant recipients infected with severe acute respiratory syndrome coronavirus 2. However, their efficacy the Omicron variant has not been reported yet.Single-center retrospective study.We included all consecutive treated antibodies for 2 infections (positive polymerase chain reaction on nasopharyngeal swab) between June 10, 2021, and January 14, 2022. Forty-seven were included. All patients had...
The pandemic of respiratory disease (COVID-19) caused by severe acute syndrome coronavirus 2 (SARS-CoV-2) is life-threatening in peritoneal dialysis (PD) patients. In PD patients with systemic viral infections, effluent may be theoretically contaminated. We searched for the presence SARS-CoV-2 genetic material real-time reverse transcriptase–polymerase chain reaction assays serial effluents three infected Nasopharyngeal swabs obtained at admission showed high load all patients, whereas none...
BackgroundHealthcare workers (HCWs) are at high risk of acquiring COVID-19 and could play a role in nosocomial transmission. Since 4th February 2020, Belgian Health authorities reported more than 90,568 cases, which 8.3% were HCWs. Data on clinical characteristics, sources infection humoral immune response HCWs with remain scarce.AimTo analyse the response, contamination, outcomes among COVID-19.MethodsThis retrospective study included 176 laboratory-confirmed teaching hospital Belgium....
Evidence regarding the role of cellular immunity in protecting against COVID-19 is emerging. To better assess immune status, simple and robust assays measuring specific T-cell responses associated with humoral are needed. We aimed to evaluate Quan-T-Cell SARS-CoV-2 test for vaccinated healthy immunosuppressed subjects.
The first wave of coronavirus disease 2019 (COVID-19) was particularly dramatic for kidney transplant recipients (KTRs) around the world.1 A recent European registry study showed 28-day mortality and intensive care unit (ICU) admission rates at 22% 21%, respectively.2 In United States, a multicenter cohort revealed rate 18%.3 Fortunately, patients from our tertiary KT center were less impacted with ICU 11% 11%, respectively.4 Like many countries, Belgium is currently facing its COVID-19...
The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. safety systemic anti-cancer therapy in oncology patients with non-severe COVID-19 is an important matter daily practice.ONCOSARS-1 was a single-center, academic observational study. Adult solid tumors treated day unit during initial phase Belgium were prospectively included. All (n = 363)...